http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021145543-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3f4111205626392f051303e7b8819 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2020-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3080c58ba9dd6029269bf8dfaa1fd17 |
| publicationDate | 2021-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021145543-A1 |
| titleOfInvention | Conjugate consisting of extracellular matrix and anticancer drug, and medical use thereof |
| abstract | The present invention relates to an extracellular matrix (REP)-anticancer drug conjugate, the extracellular matrix consisting of an elastin-like polypeptide and an integrin receptor ligand, and to medical use thereof. The extracellular matrix (REP)-doxorubicin conjugate exhibits greatly improved anticancer activity as compared to doxorubicin or a mixture of an REP and doxorubicin, and it has been confirmed that the conjugate has the effect of suppressing the drug resistance of cancer cells that exhibit resistance to doxorubicin. Thus, the extracellular matrix (REP)-doxorubicin conjugate can be provided as a pharmaceutical composition for suppressing the drug resistance of cancer cells that exhibit drug resistance to anticancer therapeutic agents and anticancer drugs, which are effective for the treatment of cancer diseases. |
| priorityDate | 2020-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 129.